KEI Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead (and NIH Response)

(UPDATE: The NIH provided responses to our comments on August 14, 2019: 84 FR 33272  Response and  84 FR 33270 Response) On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI,… Continue Reading

KEI Letter to US House Oversight Committee on NIH Misconduct and Lack of Transparency

On July 22, 2019, Knowledge Ecology International submitted a letter to the US House of Representative’s Committee on Oversight and Reform regarding the National Institutes of Health’s (NIH) lack of transparency in its exclusive licensing processes. Prior to executing an… Continue Reading

KEI letter to FTC regarding interoperability remedies to address unlawful and anti-competitive actions by Facebook

KEI letter to FTC regarding interoperability remedies to address unlawful and anti-competitive actions by Facebook Today KEI sent a letter to the U.S. Federal Trade Commission (FTC), asking that the FTC require Facebook to extend interoperability remedies to third party… Continue Reading

Joint comments on NIH patent license to Molecular Targeting Technologies, Inc. over Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors (and the NIH’s Response)

(UPDATE: The NIH provided a response to our comments on August 28, 2019) On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063 on the “Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics… Continue Reading

Joint comments on proposed NIH patent license to Tailored Therapeutics for the development and commercialization of cell therapies for cancer (and the NIH’s Response)

(UPDATE: The NIH provided a response to our comments on July 11, 2019) On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063, on the “Prospective Grant of an Exclusive Patent License: Development… Continue Reading

Delinkage, TRIPS flexibilities, and alternative incentive frameworks emerge as flashpoints during Human Rights Council’s discussions on Access to Medicines and Vaccines

UPDATE: On 4 July 2019, the Core Group will submit a “TABLING REV 1” version of their resolution on “Access to medicines and vaccines in the context of the right of everyone to the enjoyment of the highest attainable standard… Continue Reading